𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Low frequency of CDKN2 mutation in endometrial carcinomas

✍ Scribed by Stacia L. Peiffer; Detlef Bartsch; Alison J. Whelan; David G. Mutch; Thomas J. Herzog; Paul J. Goodfellow

Publisher
John Wiley and Sons
Year
1995
Tongue
English
Weight
309 KB
Volume
13
Category
Article
ISSN
0899-1987

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

The CDKN2 gene on chromosome 9p21 encodes the p16 inhibitor of cyclin D/cyclin‐dependent kinase 4 complexes. Mutations and deletions of CDKN2 have been frequently identified in cell lines, whereas most primary tumors have demonstrated a lower frequency of alteration. To assess the role of CDKN2 in endometrial tumorigenesis, 34 tumor samples were examined for loss of heterozygosity at 9p21 and mutation in CDKN2. To identify tumors that had lost 9p21, samples were genotyped with markers flanking the CDKN2 locus. The frequency of CDKN2 mutation in endometrial carcinomas was determined by single‐strand conformation variant analysis and direct sequencing of variants. Of the 34 tumors examined, three revealed loss of 9p21 sequences. Two samples were characterized by point mutations in CDKN2, one of which also showed loss of 9p21 sequences. © 1995 Wiley‐Liss, Inc.

📜 SIMILAR VOLUMES

Low frequency of BRAF and CDKN2A mutatio
Low frequency of BRAF and CDKN2A mutations in endometrial cancer
✍ Helga B. Salvesen; Rajiv Kumar; Ingunn Stefansson; Sabrina Angelini; Nicola MacD 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 French ⚖ 196 KB 👁 1 views

## Abstract Several pathways have been implicated in the pathogenesis of endometrial carcinoma. Based on recent reports, __BRAF__ mutations provide an alternative route for activation of the RAS signalling pathway. The __CDKN2A (p16)__ tumour suppressor gene is also altered in several tumour types.

Low frequency of p16/CDKN2 gene mutation
Low frequency of p16/CDKN2 gene mutations in esophageal carcinomas
✍ Asunción Esteve; Ghyslaine Martel-Planche; Bakary S. Sylla; Monica Hollstein; Pi 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 French ⚖ 515 KB

Mutational analysis of the pl6ICDKN2 gene was conducted by direct sequencing of the whole coding sequence (exom 1-3 and flanking splicing sites) in 21 esophageal squamous-cell carcinomas and 3 adenocarcinomas from a high-incidence area of Italy. Two inactivating mutations were found in exon I of the

Retention of the CDKN2A locus and low fr
Retention of the CDKN2A locus and low frequency of point mutations in primary and metastasic cutaneous malignant melanoma
✍ Anna Ruiz; Susana Puig; Michael Lynch; Teresa Castel; Xavier Estivill 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 French ⚖ 124 KB 👁 2 views

CDKN2A has been found mutated in melanoma families which show linkage to chromosome 9p21. In contrast, a low mutation rate has been found in melanomas, suggesting that CDKN2A might not be the first target for mutation in the development of this type of tumour. To elucidate the role of the CDKN2A gen

Low frequency of AXIN2 mutations and hig
Low frequency of AXIN2 mutations and high frequency of MUTYH mutations in patients with multiple polyposis
✍ Sophie Lejeune; François Guillemot; Jean-Pierre Triboulet; Stéphane Cattan; Chri 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 106 KB

## Communicated by Riccardo Fodde Familial adenomatous polyposis has been linked to germline mutations in the APC tumor suppressor gene. However, a number of patients with familial adenomatous polyposis (with either classical or attenuated phenotype) have no APC mutation. Recently, germline mutatio

Low frequency of recurrent BRCA1 and BRC
Low frequency of recurrent BRCA1 and BRCA2 mutations in Spain
✍ Gemma Llort; Carmen Yagüe Muñoz; Mercè Peris Tuser; Ignacio Blanco Guillermo; Jo 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 167 KB 👁 1 views

BRCA1 and BRCA2 mutations underlie a substantial proportion of all hereditary breast cancer. The mutational spectrum in these genes is very broad, with hundreds of different BRCA mutations reported worldwide. However, high frequency founder mutations make up a substantial fraction of all mutations i